Hansa Biopharma Year-end report January-December 2022
· Total 2022 revenue of SEK 155m · Cash runway extended into 2025 · Market Access obtained in four of the five largest European markets · Reported positive Phase 2 top-line data in AMR · Decision made to initiate clinical study with imlifidase as a pre-treatment to Sarepta’s SRP-9001 gene therapy in 2023Lund, Sweden February 2, 2023, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and Year-end report for January to December 2022. Highlights for the fourth quarter 2022 · Total Q4